Elranatamab Clinical Trials
25 recruitingDrug
Phase 213Phase 110Phase 34Phase 41
Showing 1–20 of 25 trials
Recruiting
Phase 2
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
Multiple Myeloma (MM)Multiple Myeloma, Newly Diagnosed
SCRI Development Innovations, LLC100 enrolled11 locationsNCT06974786
Recruiting
Phase 1
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
Multiple Myeloma
Pfizer87 enrolled43 locationsNCT06215118
Recruiting
Phase 3
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Multiple Myeloma
Pfizer1,116 enrolled89 locationsNCT05623020
Recruiting
Phase 3
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Multiple Myeloma
Pfizer492 enrolled274 locationsNCT06152575
Recruiting
Phase 1
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
Multiple Myeloma (MM)
C4 Therapeutics, Inc.60 enrolled16 locationsNCT07280013
Recruiting
Phase 4
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
Multiple Myeloma
Pfizer80 enrolled28 locationsNCT06057402
Recruiting
Phase 2
A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"
Relapsed Refractory Multiple Myeloma (RRMM)Extramedullary Disease in Multiple MyelomaPMD+4 more
M.D. Anderson Cancer Center34 enrolled1 locationNCT07382739
Recruiting
Phase 1
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Relapsed or Refractory Multiple Myeloma
Genentech, Inc.120 enrolled14 locationsNCT05927571
Recruiting
Phase 3
Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients
Multiple Myeloma, Newly Diagnosed
Intergroupe Francophone du Myelome824 enrolled64 locationsNCT06918002
Recruiting
Phase 3
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Multiple Myeloma
Pfizer944 enrolled238 locationsNCT05020236
Recruiting
Phase 2
Elranatamab in R/R Multiple Myeloma
Multiple MyelomaRefractory Multiple MyelomaRelapse Multiple Myeloma
Massachusetts General Hospital32 enrolled3 locationsNCT06138275
Recruiting
Phase 1Phase 2
Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis
AL Amyloidosis
Brigham and Women's Hospital49 enrolled1 locationNCT06569147
Recruiting
Phase 2
Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma
Multiple MyelomaPost-transplant MRD-guided Maintenance TherapyPre-transplant Purging
M.D. Anderson Cancer Center40 enrolled1 locationNCT06207799
Recruiting
Phase 2
Elranatamab in Relapsed/Refractory Multiple Myeloma
Multiple Myeloma
University of California, San Diego33 enrolled1 locationNCT06711705
Recruiting
Phase 1
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Multiple Myeloma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company147 enrolled19 locationsNCT06121843
Recruiting
Phase 2
Self-administration of Subcutaneous Elranatamab in the Patients' Homes.
Multiple Myeloma
Thomas Lund20 enrolled2 locationsNCT06015542
Recruiting
Phase 1Phase 2
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
Multiple Myeloma
Celgene62 enrolled22 locationsNCT06988488
Recruiting
Phase 1
A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
Multiple Myeloma
Pfizer90 enrolled39 locationsNCT05675449
Recruiting
Phase 1Phase 2
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Acute Myeloid LeukemiaHaematological Malignancy
CellCentric Ltd.250 enrolled39 locationsNCT04068597
Recruiting
Phase 2
Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma
Myeloma
H. Lee Moffitt Cancer Center and Research Institute39 enrolled1 locationNCT06947083